Dr. Guy A. Young, M.D.

Payments from drug and device companies

In 2025, 15 companies reported 256 payments worth $515,877 in total to this clinician.

What the payments were for

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in California →

Industry-funded research

Named as a principal investigator on 11 industry-funded studies in 2025, from 6 companies. The companies reported $201,014 in research payments for these studies, mostly to the institutions running them.

• Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX
  Sanofi US Services Inc. · Completed · NCT03754790
• A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B
  Regeneron Pharmaceuticals, Inc. · Recruiting · NCT06379789
• A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously Received Preventive Treatment With Emicizumab
  Genzyme Corporation · Recruiting · NCT06145373
• An open label study to determine PK and PD of Hemlibra in severe hemophilia A without inhibitors
  Genentech, Inc.
• Long-term Follow-up Study of Male Adults With Hemophilia B Previously Treated With Etranacogene Dezaparvovec (CSL222)
  Csl Behring · Enrolling by invitation · NCT05962398
• Study name not reported
  Novo Nordisk As
• STUDY TO EVALUATE THE SAFETY EFFICACY PK AND PD of Emicuzumab in mild or moderate Hemophilia A NI
  Genentech, Inc.
• HOPE-B: Trial of AMT-061 in Severe or Moderately Severe Hemophilia B Patients
  Csl Behring · Completed · NCT03569891
• Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B
  Genzyme Corporation · Completed · NCT03974113
• Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia A
  Sanofi US Services Inc. · Active, not recruiting · NCT04644575

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Pediatric Hematology & Oncology clinicians in Los Angeles

• Hisham M. Abdel-azim, MD
• Paibel I. Aguayo-hiraldo, M.D.
• Maria M. Ahmad-nabi, MD
• Shahab Asgharzadeh, MD
• Jacquelyn L. Baskin-miller, M.D.
• Vasilios Berdoukas, MD
• Erin E. Boatsman, M.D.
• Robert J. Brown, M.D.